Beyond Air is a medical devices business based in the US. Beyond Air shares (XAIR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.49 – a decrease of 7.17% over the previous week. Beyond Air employs 107 staff and has a trailing 12-month revenue of around $1.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.49 |
|---|---|
| 52-week range | $0.30 - $2.36 |
| 50-day moving average | $0.41 |
| 200-day moving average | $0.98 |
| Wall St. target price | $2.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.64 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.525 from 2024-11-19
| 1 week (2024-11-14) | -0.94% |
|---|---|
| 1 month (2024-10-21) | 46.24% |
| 3 months (2024-08-21) | 13.39% |
| 6 months (2024-05-21) | -59.30% |
| 1 year (2023-11-21) | -66.56% |
|---|---|
| 2 years (2022-11-21) | -91.37% |
| 3 years (2021-11-19) | 13.55 |
| 5 years (2019-11-21) | 4.3 |
| Revenue TTM | $1.8 million |
|---|---|
| Gross profit TTM | $873,190 |
| Return on assets TTM | -63.48% |
| Return on equity TTM | -219.18% |
| Profit margin | 0% |
| Book value | $0.55 |
| Market Capitalization | $38.3 million |
TTM: trailing 12 months
We're not expecting Beyond Air to pay a dividend over the next 12 months.
Beyond Air's shares were split on a 1:100 basis on 9 January 2017 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Beyond Air shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Beyond Air shares which in turn could have impacted Beyond Air's share price.
Over the last 12 months, Beyond Air's shares have ranged in value from as little as $0.296 up to $2.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Beyond Air's is -0.182. This would suggest that Beyond Air's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Beyond Air has bucked the trend.
Beyond Air, Inc. , a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.